RxDoctor Payments Data

Veronica Hernandez

Family · Lindsay, CANPI 1952032161

Payments from drug & device makers

$1,410in general payments, 2019–2025

Across 76 payments — averaging $18.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$338
  • Lilly USA, LLC$174
  • Boehringer Ingelheim$153
  • Bayer$97
  • AstraZeneca$90
  • Amgen$84
  • plus $474 from 16 others

What the payments were for

  • Food & beverage$1,410100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,410 in reported general payments places this provider in the 80th percentile of 10,634 family providers in California.

See all family providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide13$11,888
OzempicSemaglutide11$11,089
Pregabalin17$930
Albuterol Sulfate HfaAlbuterol Sulfate34$830
Levothyroxine Sodium18$642
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen15$436
Atorvastatin Calcium78$362
Tamsulosin Hcl21$283
Lisinopril42$254
Omeprazole35$245
Metformin Hcl43$244
Fluticasone Propionate20$172
Gabapentin14$169
Diclofenac Sodium14$158
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst12$131

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$174$11,88813 claims
Novo NordiskOzempic$40$11,08911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,634 family providers in California.

Other family in Lindsay

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →